Gene · 100306940
FL1: Follicular lymphoma, susceptibility to, 1
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. FL1: Follicular lymphoma, susceptibility to, 1. Genes, record 100306940. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/100306940
On this page
Gene
- Symbol
- FL1
- Name
- Follicular lymphoma, susceptibility to, 1
- NCBI Gene ID
- 100306940
- Type
- unknown
Source NCBI Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants695
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FL1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| ZIAHD002400 | The Role Of Subclinical Infection And Cytokines In Preterm Parturition | 5 | 2025 |
| P30CA118100 | University of New Mexico Cancer Center Support Grant | 3 | 2025 |
| P30AI027757 | University of Washington/Fred Hutch Center for AIDS Research | 2 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 2 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 2 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 2 | 2025 |
| ZIADK031115 | Functionalized Congeners of Bioactive Compounds | 2 | 2025 |
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 2 | 2025 |
1 to 10 of 695Source NIH's project files
See all 695 nih grantsPapers1,399
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Theoretical study on the cooperative effects of solvent and π-conjugation extension as well as InterHB on the fluorescent properties and ESIPT behaviors of flavonol fluorophores. | Spectrochim Acta A Mol Biomol Spectrosc | 2027 | 42520732 | PubTator, text mining | PubMed |
| Functional Analysis of the Histidine N-Methyltransferase SETD3 in Endometriosis. | Int J Mol Sci | 2026 | 42450335 | PubTator, text mining | PubMed |
| Autophagy inhibition potentiates the antileukemic effect of FLT3 inhibitors and overcomes resistance in FLT3-ITD acute myeloid leukemia. | Cell Death Discov | 2026 | 41876469 | PubTator, text mining | PubMed |
| Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation. | Signal Transduct Target Ther | 2026 | 41872160 | PubTator, text mining | PubMed |
| Chlorpromazine activates cGAS-STING signaling and reprograms the immune response in glioblastoma. | Front Immunol | 2026 | 41782888 | PubTator, text mining | PubMed |
| Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis. | Front Immunol | 2026 | 41756284 | PubTator, text mining | PubMed |
| Formulation, Characterization, and In Vitro Biological Evaluation of a Triple-Phytochemical Nano Delivery System for Colon Cancer Therapy-A Preliminary Feasibility Study. | Pharmaceutics | 2026 | 41755018 | PubTator, text mining | PubMed |
| Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells. | Curr Issues Mol Biol | 2026 | 41751491 | PubTator, text mining | PubMed |
| Automated Intracellular Immunofluorescence Staining Enabled by Magnetic 3D Mixing in a Modular Microfluidic Platform. | Biosensors (Basel) | 2026 | 41744738 | PubTator, text mining | PubMed |
| Nutrient Restriction Improves the Therapeutic Efficacy of Sorafenib by Inducing Ferroptosis via the NRF2/HO-1/GPX4 Pathway in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | 41737774 | PubTator, text mining | PubMed |
1 to 10 of 1,399
See all 1,399 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/100306940
GET https://conductscience.org/api/genes/v1/100306940/grants?page=2